Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma

Table 1 Life-months gained

Melanoma treatment	Life-months over all available follow-up	Projected life-months for all drugs up to 7 years^b
Melanoma treatment	Life-months^a	Weibull	Exponential	Gompertz	Log-normal
Ipilimumab	28.52	N/A	N/A	N/A	N/A
Dabrafenib	21.47	26.51^c	30.03	26.50	30.52
Trametinib	7.32	21.25^c	26.53	16.94	36.69
Vemurafenib	13.00	14.28^c	20.65	13.69	18.10
Dabrafenib + trametinib	16.78	24.55^c	36.75	21.88	33.12

^aLife-months were calculated by the area under the curve of the Kaplan–Meier curves of overall survival for different drugs
^bParametric survival modeling was used to extrapolate the survival probabilities of dabrafenib, trametinib, vemurafenib, and dabrafenib + trametinib. Weibull model was used as the primary model (results denoted with ^c). Other parametric models (exponential, Gompertz, and log-normal) were used as sensitivity analysis

ISSN: 2162-3619